Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?

Radiation Oncology Investigations

Volumn 7, Issue 4, 1999, Pages 249-259

  Horwitz, Eric M ^a   Hanlon, Alexandra L ^a   Pinover, Wayne H ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Androgen ablation; Biochemical control; Prostate specific antigen; Prostatic neoplasms; Radiation therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032886848     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:4<249::AID-ROI7>3.0.CO;2-V     Document Type: Article

References (25)

1. Bolla M, Gonzales D, Warde P, Dubois JB, Mirimanoff R, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
2. Granfors T, Modig H, Damber J-E, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159:2030-2034.
3. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG Protocol 85-31. J Clin Oncol 1997;15:1013-1021.
4. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45: 616-623.
5. Pilepich MV, Winter K, Roach M, Russell AH, Sause WT, Rubin P, Byhardt R, Machtay M, Grignon D. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998;42:177.
6. Aus G, Abrahamsson P-A, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998;159:2013-2017.
7. Goldenberg SL, Klotz LH, Srigley J, Jewett MAS, Mador D, Fradet Y, Barkin J, Chin J, Paquin J-M, Bullock MJ, LaPlante S. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996;156:873-877.
8. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154:424-428.
9. Witjes WPJ, Schulman CC, Debruyne FMJ. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3N0M0 prostatic carcinoma. Urology 1997;49:65-69.
10. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-1091.
11. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996;155:213-219.
12. Van Poppel H, DeRidder D, Elgamal AA, Van DeVoorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995; 154:429-434.
13. Anderson PR, Hanlon AL, Movsas B, Hanks GE. Prostate cancer patient subsets showing improved bNED control with androgen deprivation. Int J Radiat Oncol Biol Phys 1997;39:1025-1030.
14. American Joint Committee on Cancer. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for the staging of cancer. Philadelphia: JB Lippincott; 1992. p 181-186.
15. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-510.
16. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia LR. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37: 543-550.
17. Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996;35:251-257.
18. Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. The ASTRO Consensus Guidelines definition of biochemical failure is an inappropriate endpoint for prostate cancer patients receiving androgen deprivation with radiation therapy. Int J Radiat Oncol Biol Phys, submitted.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-481.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
21. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
22. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3-11.
23. Hanks GE, Hanlon AL, Schultheiss TE, Freedman GM, Hunt M, Pinover WH, Movsas B. Conformal external beam treatment of prostate cancer. Urology 1997;50: 87-92.
24. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, Lichter AS. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:311-317.
25. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, Brabbins DS, Hollander J, Chen PY, Martinez AA. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996; 36:565-571.